Amgen expands crackdown on what it says is misuse of 340B program

Amgen is intensifying its efforts to combat alleged fraud within the 340B federal drug discount program by expanding its claims data requirements for pharmacies. The company asserts that these new policies are necessary to address misuse of the program, which is designed to provide discounted medications to eligible healthcare providers.